SCHEMBL31060895

SCHEMBL31060895

CCC1SC(Nc2ccccc2C)=NC1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.47
LMNA P02545 3/20 0.47
MAPT P10636 5/20 0.41
ALDH1A1 P00352 5/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
KDM4E B2RXH2 2/20 0.41
SMN1; SMN2 Q16637 4/20 0.40
HSD11B1 P28845 1/20 0.40
C1R P00736 1/20 0.38
THRB P10828 2/20 0.38
MAPK1 P28482 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE7A Q13946 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
RAB9A P51151 2/20 0.36
GAA P10253 2/20 0.36
NPC1 O15118 1/20 0.36
TP53 P04637 1/20 0.36
MAPK10 P53779 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1383954 1.00 HPGD (0.47) HPGDLMNAMAPTALDH1A1MEN1
SCHEMBL1383105 0.84 CDK5 (0.39) HPGDMAPTALDH1A1KMT2ASMN1; SMN2
SCHEMBL1386055 0.82 CCR4 (0.38) MAPTKMT2AHSD11B1L3MBTL1NPC1
Bromide SCHEMBL6507724 0.80 LMNA (0.40) HPGDLMNAMAPTALDH1A1MEN1
SCHEMBL1383097 0.78 LMNA (0.51) HPGDLMNAMAPTALDH1A1MEN1
SCHEMBL6501525 0.77 TSHR (0.43) HPGDLMNAMAPTALDH1A1MEN1
SCHEMBL1604395 0.74 LMNA (0.47) HPGDLMNAMAPTALDH1A1MEN1
SCHEMBL1604478 0.73 LMNA (0.46) HPGDLMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL5016459 0.71 LMNA (0.44) HPGDLMNAMAPTALDH1A1MEN1
SCHEMBL20899953 0.69 TAAR1 (0.40) LMNAMAPTKMT2AMAPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4662319-A2 PERSONALIZED CRISPR PROFILING FOR CANCER Integrate Bioscience LLC (US) 2025-12-17 EP disclosed
WO-2024168301-A2 PERSONALIZED CRISPR PROFILING FOR CANCER FUNCTION ONCOLOGY, INC. (US) 2024-08-15 WO disclosed